Advanced ocular surface squamous cell carcinoma (OSSC): long-term follow-up.
Advanced ocular surface squamous neoplasia
Exenteration
Ocular surface squamous carcinoma
Orbit
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
20
12
2020
accepted:
31
05
2021
revised:
22
03
2021
pubmed:
21
7
2021
medline:
21
10
2021
entrez:
20
7
2021
Statut:
ppublish
Résumé
To analyze the clinical characteristics and long-term follow-up of patients with advanced ocular surface squamous cell carcinoma (OSSC) involving periocular tissues and/or orbit. Primary outcomes were overall survival (OS), disease-free survival (DFS), and overall recurrence rate (RR). Secondary outcomes were a correlation between primary outcomes and tumor location, American Joint Committee on Cancer Classification (AJCC) staging system, histological results, surgical margins, and type of treatment. a retrospective case series. The medical records of patients affected by OSSC involving periocular tissues and/or orbit referring, from 01/2011 to 01/2020, to our tertiary referral center were reviewed. Thirty-six eyes of 36 patients were included. The mean age was 68.2 years; 18 (50%) patients were males. The mean follow-up was 40 months. The RR was 64%. The OS at 12, 24, 36, and 60 months was respectively 97.1%, 92.7%, 92.7%, and 92.7%. The DFS at 12, 24, 36, and 60 months was respectively 62.9%, 50.8%, 41.6%, and 29.7%. Multicentric disease (p = 0.0039), inferior tarsus localization (p = 0.0428), histological diagnosis of high-risk SSCs (p = 0.0264), positive surgical margins (p = 0.0434), and excisional biopsy (EB) alone (p = 0.0005) were associated with an increased risk of recurrence. A shorter OS was observed in patients who underwent EB alone (p = 0.0049). OSCC involving periocular tissues and/or orbit is an aggressive disease with a high recurrence rate. Multicentric disease, positive surgical margins, inferior tarsus localization, and surgery without adjuvant therapies are strong predictors of recurrence and are the main factors affecting prognosis.
Identifiants
pubmed: 34283293
doi: 10.1007/s00417-021-05264-3
pii: 10.1007/s00417-021-05264-3
pmc: PMC8523462
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3437-3443Informations de copyright
© 2021. The Author(s).
Références
Shields CL, Alset AE, Boal NS et al (2017) Conjunctival tumors in 5002 cases. Comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen Lecture Am J Ophthalmol 173:106–133
doi: 10.1016/j.ajo.2016.09.034
Emmanuel B, Ruder E, Lin SW, Abnet C, Hollenbeck AR, Mbulaiteye SM (2012) Incidence of squamous-cell carcinoma of the conjunctiva and other eye cancers in the NIH-Diet AARP and Study Health. Ecancermedicalscience 6:254
pubmed: 22654961
pmcid: 3357182
Sun EC, Fears TR, Goedert JJ (1997) Epidemiology of squamous cell conjunctival cancer. Cancer Epidemiol Biomarkers Prev 6:73–77
pubmed: 9037556
Shields JA, Shields CL, Suvarnamani C, Tantisira M, Shah P (1991) Orbital exenteration with eyelid sparing: indications, technique and results. Ophthalmic Surg 22:292–297
pubmed: 1852385
Polski A, Sibug Saber M, Kim JW, Berry JL (2019) Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia. Clin Exp Ophthalmol 47(2):193–200
doi: 10.1111/ceo.13382
Arepalli S, Kaliki S, Shields CL, Emrich J, Komarnicky L, Shields JA (2014) Plaque radiotherapy for scleralinvasive conjunctival squamous cell carcinoma: analysis of 15 eyes. JAMA Ophthalmol 132:691–696
doi: 10.1001/jamaophthalmol.2014.86
Yousef YA, Finger PT (2012) Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases. Ophthalmology 119(2):233–240
doi: 10.1016/j.ophtha.2011.08.005
Erie JC, Campbell RJ, Liesegang TJ (1986) Conjunctival and corneal intraepithelial and invasive neoplasia. Ophthalmology 93(2):176–183
doi: 10.1016/S0161-6420(86)33764-3
Shields JA, Shields CL, Gunduz K, Eagle RC Jr (1999) The 1998 Pan American Lecture: intraocular invasion of squamous cell carcinoma of the conjunctiva in five patients. Ophthal Plast Reconstr Surg 15(3):153–160
doi: 10.1097/00002341-199905000-00003
Soysal HG, Ardiç F (2008) Malignant conjunctival tumors invading the orbit. Ophthalmologica 222(5):338–343
doi: 10.1159/000146079
Galor A, Karp CL, Oellers P, Kao AA, Abdelaziz A, Feuer W, Dubovy SR (2012) Predictors of ocular surface squamous neoplasia recurrence after excisional surgery. Ophthalmology 119(10):1974–1981
doi: 10.1016/j.ophtha.2012.04.022
Shields CL, Shields JA (2019) Tumors of the conjunctiva and cornea. Indian J Ophthalmol 67(12):1930–1948
doi: 10.4103/ijo.IJO_2040_19
Lee GA, Hirst LW (1995) Ocular surface squamous neoplasia. Surv Ophthalmol 39:429–450
doi: 10.1016/S0039-6257(05)80054-2
Rootman J, Stewart B, Goldberg RA (1995) Orbital surgery. A conceptual approach. Chapter 7, Orbital Anatomy. Philadelphia, Lippincott-Raven, pp 134–136
Shields JA, Shields CL, De Potter P (1997) Surgical management of conjunctival tumors. Arch Ophthalmol 115(6):808–815
doi: 10.1001/archopht.1997.01100150810025
Midena E, Angeli CD, Valenti M, de Belvis V, Boccato P (2000) Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol 84:268–272
doi: 10.1136/bjo.84.3.268
Shields CL, Naseripour M, Shields JA (2002) Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol 133:601–606
doi: 10.1016/S0002-9394(02)01400-9
Blasi MA, Maceroni M, Sammarco MG, Pagliara MM (2018) Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study. Eur J Ophthalmol 28(2):204–209
doi: 10.5301/ejo.5001035
Nagarajan P, El-Hadad C, Gruschkus SK, Ning J, Hudgens CW, Sagiv O, Gross N, Tetzlaff MT, Esmaeli B (2019) PD-L1/PD1 expression, composition of tumor-associated immune infiltrate, and HPV status in conjunctival squamous cell carcinoma. Invest Ophthalmol Vis Sci 60(6):2388–2398
doi: 10.1167/iovs.19-26894
Wolkow N, Jakobiec FA, Afrogheh AH, Eagle RC Jr, Pai SI, Faquin WC (2019) Programmed cell death 1 ligand 1 and programmed cell death 1 ligand 2 are expressed in conjunctival invasive squamous cell carcinoma: therapeutic implications. Am J Ophthalmol 200:226–241
doi: 10.1016/j.ajo.2018.12.020
Demirci H, Elner VM, Demirci FY, Robinson DR, Chinnaiyan A, Schlachter D, Joseph S, Worden F (2020) Immunotherapy for conjunctival squamous cell carcinoma with orbital extension. Ophthalmology S0161–6420:30932–30935